Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.
One-third of aggressive breast cancer patients delay starting further treatment after immunotherapy, highlighting a care gap needing urgent attention.
In a multicenter real-world Italian cohort, 32.7% of triple-negative breast cancer patients with metastatic recurrence after neoadjuvant chemo-immunotherapy failed to initiate first-line systemic therapy within 90 days. Shorter disease-free interval, PD-L1 positivity, and CNS metastases were independent predictors of this therapeutic attrition, identifying a significant care gap requiring earlier intervention strategies.
What the study was
- Study design
- retrospective multicenter cohort study
- Population
- TNBC patients with metastatic recurrence after neoadjuvant chemo-immunotherapy (multicenter Italian)
- Category
- Public Health
- Maturity
- Validated
- Journal
- Breast cancer research and treatment
Why it surfaced
Identifies a significant care gap (one-third of post-neoICI TNBC patients never receive first-line therapy) with prognostic implications; multicenter Italian real-world study; relevant to immunotherapy watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.